GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lumos Pharma Inc (NAS:LUMO) » Definitions » Price-to-Owner-Earnings

Lumos Pharma (Lumos Pharma) Price-to-Owner-Earnings : (As of Jun. 19, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Lumos Pharma Price-to-Owner-Earnings?

As of today (2024-06-19), Lumos Pharma's share price is $2.20. Lumos Pharma does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Lumos Pharma's Price-to-Owner-Earnings or its related term are showing as below:

During the past 13 years, the highest Price-to-Owner-Earnings of Lumos Pharma was 22.36. The lowest was 9.49. And the median was 14.04.


LUMO's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.725
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-19), Lumos Pharma's share price is $2.20. Lumos Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-5.48. Therefore, Lumos Pharma's PE Ratio for today is At Loss.

As of today (2024-06-19), Lumos Pharma's share price is $2.20. Lumos Pharma's EPS without NRI for the trailing twelve months (TTM) ended in was $-5.48. Therefore, Lumos Pharma's PE Ratio without NRI for today is At Loss.

During the past 13 years, Lumos Pharma's highest PE Ratio without NRI was 17.11. The lowest was 0.00. And the median was 12.15.


Lumos Pharma Price-to-Owner-Earnings Historical Data

The historical data trend for Lumos Pharma's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lumos Pharma Price-to-Owner-Earnings Chart

Lumos Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Lumos Pharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Lumos Pharma's Price-to-Owner-Earnings

For the Biotechnology subindustry, Lumos Pharma's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lumos Pharma's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lumos Pharma's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Lumos Pharma's Price-to-Owner-Earnings falls into.



Lumos Pharma Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Lumos Pharma's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=2.20/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lumos Pharma  (NAS:LUMO) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Lumos Pharma Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Lumos Pharma's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Lumos Pharma (Lumos Pharma) Business Description

Traded in Other Exchanges
N/A
Address
4200 Marathon Boulevard, Suite 200, Austin, TX, USA, 78756
Lumos Pharma Inc is a biopharmaceutical company that develops treatments for cancer and rare diseases. It carries out both clinical-stage and preclinical research on a range of molecules that help the immune system fight off cancer cells. The treatments are available orally and can be used in conjunction with other cancer therapies. The company also researches an Ebola vaccine. Lumos contracts with manufacturing organizations to make their treatments, engages in partnerships with pharmaceutical companies, and operates primarily in the United States.
Executives
David B Karpf officer: Chief Medical Officer 1360 WILLOW ROAD #100, MENLO PARK CA 94025
Aaron Schuchart officer: Chief Business Officer C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S.MOPAC EXPWY,BARTONOAKSPLAZONE,#250, AUSTIN TX 78746
Es-johansson An Van director 6863 BEE CAVE ROAD, SUITE 200, AUSTIN TX 78736
James E Flynn 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Joseph S Mccracken director C/O NEXVET BIOPHARMA PLC, NATL INST, FOSTERS AVENUE, MOUNT MERRION, BLACKROCK L2 00000
Richard J Hawkins director, officer: Chief Executive Officer 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404-2125
Emmett Cunningham director C/O RESTORATION ROBOTICS, INC., 128 BAYTECH DRIVE, SAN JOSE CA 95134
Kevin M. Lalande director 201 WEST 5TH STREET, AUSTIN TX 78701
John C. Mckew officer: Chief Scientific Officer C/O LUMOS PHARMA, 4200 MARATHON BLVD, STE 200, AUSTIN TX 78756
Deerfield Mgmt Iii, L.p. 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Private Design Fund Iii, L.p. 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Management Company, L.p. (series C) 10 percent owner, other: Possible Member of 10% Group 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Bradley J Powers officer: Principal Executive Officer C/O NEWLINK GENETICS CORPORATION, 2503 SOUTH LOOP DRIVE, AMES IA 50010
Lori D Lawley officer: Principal Accounting Officer C/O NEWLINK GENETICS CORPORATION, 2503 SOUTH LOOP DRIVE, AMES IA 50010
Ernest Iii Talarico director C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AIMES IA 50010